Science & Enterprise subscription

Follow us on Twitter

  • A solid majority of Americans now says that climate change affects their communities, a finding that could affect f… https://t.co/FeSjrqpv7t
    about 3 hours ago
  • New post on Science and Enterprise: Infographic – Most in US Say Climate Change Affects Them https://t.co/5N2p07v38r #Science #Business
    about 3 hours ago
  • Many thanks @deansguide for the shout-out and all of your good work for lung health. I just report on stuff. Enjoy… https://t.co/nrNcveHCJM
    about 22 hours ago
  • A company developing 3-D printed outer ear tissue received a rare pediatric disease designation on its treatment de… https://t.co/Iya45fwEl2
    about 22 hours ago
  • New post on Science and Enterprise: Bioprinting Ear Tissue Tagged Rare Disease Treatment https://t.co/Cr90bNUF2E #Science #Business
    about 22 hours ago

Please share Science & Enterprise

Pain Therapy Developer Issues IPO, Raises $55 Million

Back pain (FDA)

(U.S. Food and Drug Administration)

31 January 2014. Cara Therapeutics Inc., a biotechnology company in Shelton, Connecticut, issued its initial public offering (IPO), raising some $55 million. The company issued 5 million shares of common stock, priced in the range of $11 to $13 a share. At noon ET today, the stock is priced at $13.38 a share on the NASDAQ exchange (symbol: CARA).

Cara Therapeutics develops medications to treat moderate to severe pain, which interact with kappa opioid receptors located on sensory nerves that transmit pain signals. Morphine is the best known drug addressing mu opioid receptors that also reside in sensory nerves, but it comes with serious side effects, including the risk of abuse and addiction.

The company’s lead product is code-named CR845 that stimulates kappa opioid receptors and exhibits both pain-killing and anti-inflammatory properties, without the addictive effects of morphine. The company completed tests of an intravenous form of the drug in intermediate-stage clinical trials to treat pain after hysterectomy and bunion surgery, with late-stage trials planned for later in 2014. An oral form of the drug is in early-stage trials.

Cara Therapeutics is also developing pain medications addressing cannabinoid or CB receptors, specifically CB2 receptors located in peripheral tissues; CB1 receptors are located in the brain. The company’s lead product, code-named CR701, is in preclinical research and targets CB2 receptors. CR701 is expected to be developed as a treatment for neuropathic pain, caused by damaged nerve fibers.

The company raised $43 million in venture capital from four financing rounds, the most recent in 2010, where it gained $15 million for continued clinical development of CR845.

Read more:

Hat tip: Fortune/Term Sheet

*     *     *

Please share Science & Enterprise ...
error

Comments are closed.